PERSPECTIVES OF COOPERATION PHARMENA SA Pharmena was founded in - - PowerPoint PPT Presentation

PERSPECTIVES

OF COOPERATION

PHARMENA SA

• Pharmena was founded in 2002 to develop &

commercialize an active substance 1-methylnicotinamide

• Headquartered in Lodz, Poland
• Publicly

traded

• n

the Warsaw Stock Exchange (WAR:PHR)

• Engaged in the discovery, development and

market

• f

innovative products for dermatological and other conditions

• Dermatoligical

areas

• f

focus include alopecia (hair loss), inflammatory dermatoses, acne, burn healing as well as anti-wrinkle

RESEARCH

• PHARMENA

is focused

• n

the search for innovative, unique solutions, which have resulted in numerous patent applications and granted patents

• Involved in research on new medicines for the

treatment

• f

cardiovascular and

• ther

disorders based upon the proprietary active ingredient (1-MNA) used in its dermatological products

• Established a dominant IP position for both

topical and systemic uses of 1-MNA and owns the US IND and Canadian CTA regulatory filings

& DEVELOPMENT

1-METHYLNICOTINAMIDE

(1-MNA)

• 1-methylnicotinamide

is previously unexplored metabolite

• f

nicotinic acid and a catabolite

• f

nicotinamide, which is one of the two main forms of the B-complex vitamin niacin (niacin = nicotinic acid and/or nicotinamide)

• 1-MNA is produced endogenously by the metabolism of

dietary nicotinamide

• 1-MNA can also be obtained directly by consumption of

various foods high in vitamin B3 (e.g., pork ham, wakame, and a variety of Japanese tea; Taguchi et al., 1986)

• 1-MNA

provides significant anti-inflammatory and additional therapeutic benefits when administrated to the skin

• The molecule is chemically stable and well tolerated by

human organism

THREE

• 1. COSMECEUTICALS
• Portfolio of products with patent protection
• World Market Value in 2012: 32 billion USD

BUSINESS LINES

THREE

• 2. DIETARY SUPPLEMENT (NOVEL FOOD)
• Innovative product based on 1-MNA –

prevention of atherosclerosis (anti- inflamatory benefits)

• European Market Value in 2011: around

500 MM USD (including only omega-3 products)

BUSINESS LINES

THREE

• 3. DRUG DEVELOPMENT
• Phase

2 Candidate, TRIA-662, Demonstrates Potential to Provide Benefits

• f Niacin Therapy without Flushing
• TRIA-662 would address a $40 billion plus

market including niacin, fenofibrate, statin and omega-3 fatty acid products

BUSINESS LINES

COSMECEUTICALS

PRODUCTS

RESEARCH

• Well diversified portfolio covering multiple

indications as well as

• ffering

several differing formulations

• The

cosmeceutical products are sold exclusively through drug stores

• All

product’s safety & claims are supported by human trials involving over 1000 people

& DEVELOPMENT

HAIR CARE

• A

comprehensive approach to the problem

• f

hair loss, eyebrow and eyelashes weakness and loss

• Innovative solutions
• Efficiency confirmed in dermatological

trials

• Broad product portfolio: shampoos, gels,

conditioners, ampules, lotion, maskara and dietary suplement

PRODUCTS

SKIN CARE

PRODUCTS

OPPORTUNITY

• PHARMENA has a diversified topical portfolio

covering multiple indications and in some cases including several formulations for an indication

• PHARMENA’s portfolio of dermocosmetics is

currently generating nearly $5MM in revenue with products only marketed within Poland and rised by over 50% in 2013

• Over

The Counter (OTC) availability

• f

product provides quick market entry for prospective partner

HIGHLIGHTS #1

OPPORTUNITY

• Uniqueness

in the world scale – patented, natural, active substance 1-methylnicotinamide

• Competitive price

policy including volume discounts

• Exclusive distribution rights
• Fit

a distributor requirements – individual packaging design available depended on local needs

HIGHLIGHTS #2

THANK YOU

FOR YOUR TIME